ViGenCell, Inc. engages in the research and development of pharmaceutical and immune cell therapy products. Its products pipeline includes ViTier, ViMedier, and ViRanger. The company was founded on February 1, 2013 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company